Gilead Tops Profit Estimates, Raises 2015 Sales ForecastBy
Biotech's third-quarter revenue surges 37% to $8.3 billion
Hepatitis drug Sovaldi beats expectations, Harvoni misses
Gilead Sciences Inc., maker of the hepatitis C drugs Sovaldi and Harvoni, posted third-quarter profit that topped analysts’ estimates and raised its forecast for the year.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.